Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi

Cancer

Volumn 75, Issue 11, 1995, Pages 2768-2778

  Braichotte, Daniel R ^a   Wagnières, Georges A ^a   Bays, Roland ^a   Monnier, Phillipe ^a,b   Van Bergh, Hubert E Den ^a  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

bronchi; early stage carcinoma; esophagus; fluorescence; hematoporphyrin derivative; oral cavity; pharmacokinetics; photodynamic therapy; spectroscopy

Indexed keywords

PHOTOFRIN;

ADULT; AGED; ANIMAL MODEL; ARTICLE; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER MODEL; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; EARLY DIAGNOSIS; ESOPHAGUS CANCER; FEMALE; FLUORESCENCE SPECTROSCOPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUTH CANCER; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TISSUE DISTRIBUTION;

ADULT; AGED; BRONCHIAL NEOPLASMS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HEMATOPORPHYRIN DERIVATIVE; HUMAN; MALE; MIDDLE AGE; MOUTH NEOPLASMS; PHOTOCHEMOTHERAPY; SPECTROMETRY, FLUORESCENCE; SUPPORT, NON-U.S. GOV'T;

EID: 0029023593     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950601)75:11<2768::AID-CNCR2820751122>3.0.CO;2-I     Document Type: Article

References (56)

1. Digital background subtraction for fluorescence imaging
2. A fluorescent imaging device for endoscopic detection of early stage cancer: instrumental and experimental studies
3. Photodetection of early cancer in the upper aerodigestive tract and the bronchi using Photofrin II and colorectal adenocarcinoma with fluoresceinated monoclonal antibodies
4. Detection and localization of early lung cancer by imaging techniques
5. Photodétection et photothérapie des carcinomes épidermoĩdes précoces du pharynx, de l'oesophage et des bronches
6. Photodynamic therapy for esophageal tumors
7. Development of carcinoma of the lung as reflected in exfoliated cells
8. Outcome of carcinoma in situ and early invasive carcinoma of the bronchus
9. How does photodynamic therapy work
10. Photochemotherapy of cancer: experimental research
11. Photodynamic therapy
12. A comparison of serum kinetics and tissue distribution of photofrin II following intravenous and intraperitoneal injection in the mouse
13. Biological and biophysical properties of the tumor‐localizing component of hematoporphyrin derivative
14. Liposome‐ or LDL‐administered Zn(II)‐phtalocyanine as a photodynamic agent for rumors: I. Pharmacokinetics properties and phototherapeutic efficiency
15. Mouse skin Photosensitivity with dihaematoporphyrin ether (DHE) and aluminium sulphonated phtalocyanine (AlSPc): a comparative study
16. Determination of (3H)‐ and (14C)hematoporphyrin derivative distribution in malignant and normal tissue
17. Distribution and elimination of Photofrin II in mice
18. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse
19. Biodistribution of the photosensitizer dihaematoporphyrin ether
20. Localization and detection of fluoresceinated chimeric antibodies directed against carcinoembryonic antigen in primary colorectal carcinomas: a first approach to clinical immunophotodiagnosis
21. Fluorescence studies of hematoporphyrin derivative in normal and malignant rat tissue
22. Tissue‐localizing properties of some photosensitizers studied by in vivo fluorescence imaging
23. Pharmacokinetics of fluorescent polyporphyrin photofrin II in normal rat tissue and rat bladder tumor
24. Photofrin II pharmacokinetics and optical dosing in tissue: apparatus and clinical measurements for the pharynx, esophagus, and tracheobronchial tree
25. Pharmacokinetics of a fluorescent drug using laser induced fluorescence
26. An attempt to reduce skin photosensitivity in clinical photodynamic therapy using oral activated charcoal
27. Skin photosensitivity: duration and intensity following intravenous hematoporphyrin derivatives, HPD and DHE
28. Photodetection and photodynamic therapy of early squamous cell carcinomas of the pharynx, oesophagus and tracheo‐bronchial tree
29. Quantification of phtalocyanine concentration in rat tissue using laser‐induced fluorescence spectroscopy
30. Laser‐induced fluorescence: experimental intraoperative delineation of tumor resection margins
31. Antibody‐fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice
32. Quantification of the hematoporphyrin derivative by fluorescence measurements using dual‐wavelength excitation and dual wavelength detection
33. Analytical model for extracting intrinsic fluorescence in turbid media
34. Photosensitizers: Therapy and detection of malignant tumors
35. Probing the structure of HPD by fluorescence spectroscopy
36. Fluorescence and absorption properties of the components of haematoporphyrin derivative
37. Photophysical properties of photofrin II in different solvents
38. Intacellular fluorescence polarization, picosecond kinetics and light‐induced reactions of photosensitizing porphyrins
39. Pharmacokinetics of Photofrin in man
40. Characterization of intra‐tumoral porphyrin following injection of hematoporphyrin derivative or its purified component
41. Quantitative in vivo measurements of the fluorescent components of Photofrin II
42. Aspects of tumour demarcation in rats by means of laser‐induced fluorescence and haematoporphyrin derivatives
43. Photobleaching of porphyrins used in photodynamic therapy and implications for therapy
44. Distribution of HPD in the rat 91 gliosarcoma brain tumor as analyzed by digital video fluorescence microscopy
45. Histopathological comparison of the effects of hematoporphyrin on two different murine tumors using computer enhanced digital video fluorescence microscopy
46. Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer
47. Photodynamic therapy in the management of resistant lower urinary tract carcinoma
48. Photodynamic therapy in the treatment of malignant tumors of the skin and head and neck
49. Photoradiation therapy: II. Cure of animal tumors with hematoporphyrin and light
50. Drug and light dose dependence of photodynamic therapy: a study of tumor cell clonogenicity and histologic changes
51. Low density lipoprotein receptor pathway in the delivery of photofrin: how much is it relevant for selective accumulation of the photosensitizer in tumor?
52. The theory of photodynamic therapy dosimetry: consequences of photodestruction of sensitizer
53. Effect of drug‐light interval on photodynamic therapy with meso‐tetrahydroxyphenylchlorine in malignant mesothelioma
54. Photodynamic therapy in the treatment of pancreatic carcinoma: dihematoporphyrin ether uptake and photobleaching kinetics